

**Freedom of Information Act 2000 - Request Reference FoI/23/371**  
**Hereditary Angioedema**

**Information Requested:**

Please provide the following information:

1. The number of patients diagnosed with **Hereditary Angioedema (HAE)** types 1, 2, normal C1 and Acquired HAE.
2. The volume of medication dispensed and/or consumed from **January 1st, 2023, to June 30th, 2023**, for each of the products below. If it is more convenient to specify the number of vials, pre-filled syringes, or tablets, that would also be very helpful.

List of Medications:

lanadelumab (Takzhyro)  
pdC1-inhibitor (Cinryze and Berinert)  
rC1-inhibitor (Ruconest)  
icatibant (Firazyr and generic)  
berotralstat (Orladeyo)

**Response Details:**

1.

|  |          |             |
|--|----------|-------------|
| Period: 1 Jul 2022   | to       | 30 Jun 2023 |
| Distinct patients in period coded with diagnosis of hereditary angioedema:   | 10       |             |
| NB: Based on hereditary angioedema diagnosis codes in any diagnosis position in all Episodes. Based on Coding as of: | 7 Aug 23 |             |

**2. List of Medications:**

lanadelumab (Takzhyro): 52 pre-filled syringes  
pdC1-inhibitor (Cinryze and Berinert): 0  
rC1-inhibitor (Ruconest): 4 vials  
icatibant (Firazyr and generic): 204 pre-filled syringes  
berotralstat (Orladeyo): 504 capsules